Cargando…
Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient
Immune checkpoint inhibitors (ICIs) became the standard treatment for many different kinds of cancers and can result in a variety of immune-related adverse events (irAEs). IrAEs of kidney are uncommon and consists of different pathology types. Among the different types, membranous nephropathy (MN) i...
Autores principales: | Chen, Minjiang, Zhang, Lei, Zhong, Wei, Zheng, Ke, Ye, Wei, Wang, Mengzhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141750/ https://www.ncbi.nlm.nih.gov/pubmed/34040602 http://dx.doi.org/10.3389/fimmu.2021.619147 |
Ejemplares similares
-
Characterization of THSD7A-antibodies not binding to glomerular THSD7A in a patient with diabetes mellitus but no membranous nephropathy
por: Reinhard, Linda, et al.
Publicado: (2021) -
A rare case of PLA2R- and THSD7A-positive idiopathic membranous nephropathy
por: Wanderley, David Campos, et al.
Publicado: (2019) -
The Alternative Pathway Is Necessary and Sufficient for Complement Activation by Anti-THSD7A Autoantibodies, Which Are Predominantly IgG4 in Membranous Nephropathy
por: Manral, Pallavi, et al.
Publicado: (2022) -
Meta‐Analysis of the Diagnostic Efficiency of THSD7A‐AB for the Diagnosis of Idiopathic Membranous Nephropathy
por: Liu, Yipeng, et al.
Publicado: (2020) -
An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN
por: Ren, Song, et al.
Publicado: (2018)